Recent Quotes (30 days)

You have no recent quotes
chg | %

Response Biomedical Corp. (ADR)  

(Public, OTCBB:RPBIF)   Watch this stock  
Find more results for RPBIF
3.29
-0.20 (-5.86%)
May 17 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 3.29 - 3.29
52 week 0.95 - 5.57
Open 3.29
Vol / Avg. 1,000.00/864.00
Mkt cap 21.59M
P/E     -
Div/yield     -
EPS -0.84
Shares 6.56M
Beta 2.71
Inst. own     -
May 22, 2013
Response Biomedical Corp at Bloom Burton & Co. Healthcare Investor Conference - 3:30PM EDT - Add to calendar
May 13, 2013
Q1 2013 Response Biomedical Corp Earnings Conference Call
May 6, 2013
Q1 2013 Response Biomedical Corp Earnings Release
Mar 28, 2013
Q4 2012 Response Biomedical Corp Earnings Release
Mar 11, 2013
Q4 2012 Response Biomedical Corp Earnings Conference Call
  

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 22.73% -44.94%
Operating margin -21.22% -35.76%
EBITD margin - -26.04%
Return on average assets 18.68% -29.97%
Return on average equity - -199.41%
Employees 72 -
Carbon Disclosure Rating - -

Address

1781-75th AVENUE W
VANCOUVER, BC V6P 6P2
Canada
+1-604-4566010 (Phone)
+1-604-4566066 (Fax)

Website links

External links

Discussion Group - Google Finance

Description

Response Biomedical Corporation (Response) develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a paradigm in diagnostics that provides sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The RAMP system is a platform technology that combines a sensitive, portable fluorescence detection system with simple lateral flow immunoassays. RAMP maintains key positive attributes of lateral flow immunoassays - simplicity, specificity, reliability and rapid results - but includes a method to overcome the performance limitations of early generation immunoassays that suffer from relatively poor sensitivity and precision.

Officers and directors

Peter A. Thompson M.D. Executive Chairman of the Board
Jeffrey L. Purvin Chief Executive Officer, Director
Age: 60
W. J. Adams Chief Financial Officer, Corporate Secretary
Age: 51
Tim Shannon Senior Vice President - World Wide Sales and Marketing
Age: 47
Patricia Massitti Vice President - Administration Corporate Communication
Age: 51
Barbara Kinnaird Steen Ph.D. Vice President - Research and Development
Age: 45
Anastasios Tsonis Corporate Controller
Age: 32
Jonathan Wang Ph.D. Director
Anthony F. Holler M.D. Independent Director
Age: 61
Joseph D. Keegan Ph.D. Independent Director